The DEA is proposing to increase its 2023 production quotas for marijuana compounds and psychedelics in the context of an ongoing administrative review into the scheduling status of cannabis and potential federal approval for certain psychedelics as therapeutics. The updated quotas reflect the estimated medical, scientific, research, and industrial needs of the U.S.
- Psilocybin: from 8,000 grams to 15,000 grams
- Psilocyn: from 12,000 grams to 24,000 grams
- Ibogaine: from 30 grams to 150 grams
- Delta-9-THC: from 384,460 grams to 628,460 grams
- All other tetrahydrocannabinol: from 15,000 grams to 350,000 grams
The DEA has increased its production quotas for marijuana compounds and psychedelics in recent years, including MDMA, psilocyn, and 5-MeO-DMT. This year’s quota for marijuana is 6.7 million grams, more than double the 2022 quota. The DEA has authorized additional cannabis manufacturers, and approved cultivators can now apply to be federal marijuana suppliers for study purposes.
The DEA has faced criticism from advocates and scientists for its actions to promote research into these substances, but it has recently retreated on a proposed ban on psychedelic compounds and abandoned plans to place five tryptamine psychedelics in Schedule I.